Literature DB >> 17876506

Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.

Stefan Gebhardt1, Fabian Härtling, Markus Hanke, Frank M Theisen, Richard von Georgi, Phillip Grant, Markus Mittendorf, Matthias Martin, Christian Fleischhaker, Eberhard Schulz, Helmut Remschmidt.   

Abstract

OBJECTIVE: To examine relations between movement disorders (MD) and psychopathological symptoms in an adolescent population with schizophrenia under treatment with predominantly atypical antipsychotics.
METHOD: MD symptoms and psychopathology were cross-sectionally assessed in 93 patients (aged 19.6 +/- 2.2 years) using Tardive Dyskinesia Rating Scale (TDRS), Abnormal Involuntary Movement Scale (AIMS), Extrapyramidal Symptom Scale (EPS), Barnes Akathisia Scale (BAS), Brief Psychiatric Rating Scale (BPRS) and the Schedule for Assessment of Negative/Positive Symptoms (SANS/SAPS).
RESULTS: All patients with MD symptoms (n = 37; 39.8 %) showed pronounced global psychpathological signs (SANS/SAPS, BPRS: p = 0.026, p = 0.033, p = 0.001) with predominant anergia symptoms (p = 0.005) and inclinations toward higher anxiety- and depression-related symptoms (p = 0.051) as well as increased thought disturbance (p = 0.066). Both negative symptoms and anergia showed trends for positive correlations with tardive dyskinesia (p = 0.068; p = 0.065) as well as significant correlations with parkinsonism symptoms (p = 0.036; p = 0.023). Akathisia symptoms correlated significantly with hostile and suspicious symptoms (p = 0.013). A superfactor-analysis revealed four factors supporting the aforementioned results.
CONCLUSION: MD symptoms and psychopathology are in some respects related to each other. Motor symptoms representing on the one hand trait characteristics of schizophrenia might additionally be triggered by antipsychotics and finally co-occur with more residual symptoms within a long-term treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17876506     DOI: 10.1007/s00787-007-0633-0

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  86 in total

1.  Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status.

Authors:  A Putzhammer; M Perfahl; L Pfeiff; G Hajak
Journal:  Pharmacopsychiatry       Date:  2005-05       Impact factor: 5.788

2.  Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures.

Authors:  O Yuen; M P Caligiuri; R Williams; R A Dickson
Journal:  Br J Psychiatry       Date:  1996-06       Impact factor: 9.319

3.  High potency neuroleptics and violence in schizophrenics.

Authors:  J N Herrera; J J Sramek; J F Costa; S Roy; C W Heh; B N Nguyen
Journal:  J Nerv Ment Dis       Date:  1988-09       Impact factor: 2.254

4.  A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients.

Authors:  D Pool; W Bloom; D H Mielke; J J Roniger; D M Gallant
Journal:  Curr Ther Res Clin Exp       Date:  1976-01

5.  Tardive dyskinesia in young mentally retarded individuals.

Authors:  C T Gualtieri; S R Schroeder; R E Hicks; D Quade
Journal:  Arch Gen Psychiatry       Date:  1986-04

6.  Specificity of the Calgary Depression Scale for schizophrenics.

Authors:  D Addington; J Addington; E Maticka-Tyndale
Journal:  Schizophr Res       Date:  1994-02       Impact factor: 4.939

7.  Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia.

Authors:  Karmen K Yoder; Gary D Hutchins; Evan D Morris; Allison Brashear; Chunzi Wang; Anantha Shekhar
Journal:  Schizophr Res       Date:  2004-12-01       Impact factor: 4.939

8.  Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality.

Authors:  J L Waddington; H A Youssef; C Dolphin; A Kinsella
Journal:  Arch Gen Psychiatry       Date:  1987-10

Review 9.  Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.

Authors:  Małgorzata Pietraszek
Journal:  Pol J Pharmacol       Date:  2003 Mar-Apr

10.  Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia.

Authors:  S M Halstead; T R Barnes; J C Speller
Journal:  Br J Psychiatry       Date:  1994-02       Impact factor: 9.319

View more
  5 in total

1.  Anticholinergic use in children and adolescents after initiation of antipsychotic therapy.

Authors:  Irene Seunghyun Hong; Jeffrey R Bishop
Journal:  Ann Pharmacother       Date:  2010-06-29       Impact factor: 3.154

2.  Relationship between motor function and psychotic symptomatology in young-adult patients with schizophrenia.

Authors:  Shu-Mei Wang; Wen-Chen Ouyang; Ming-Yi Wu; Li-Chieh Kuo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-04-11       Impact factor: 5.270

3.  Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia.

Authors:  Jiajun Weng; Yan Zhang; Huafang Li; Yifeng Shen; Wenjuan Yu
Journal:  Gen Psychiatr       Date:  2019-02-23

4.  Gray matter abnormalities in schizophrenia patients with tardive dyskinesia: a magnetic resonance imaging voxel-based morphometry study.

Authors:  Cheng-Ta Li; Kun-Hsien Chou; Tung-Ping Su; Chu-Chung Huang; Mu-Hong Chen; Ya-Mei Bai; Ching-Po Lin
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

5.  A Cross-Sectional Study on the Characteristics of Tardive Dyskinesia in Patients with Chronic Schizophrenia.

Authors:  Yanan Huang; Lizhen Pan; Fei Teng; Geying Wang; Chenhu Li; Lingjing Jin
Journal:  Shanghai Arch Psychiatry       Date:  2017-10-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.